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Introduction {#ehf212668-sec-0001}
============

The two main types of amyloidosis that affect the heart are light chain (AL) and transthyretin.[1](#ehf212668-bib-0001){ref-type="ref"}, [2](#ehf212668-bib-0002){ref-type="ref"} Multiple myeloma and AL amyloidosis can occur together in \~5--10% of patients (predominantly male patients and median age is 63 years).[2](#ehf212668-bib-0002){ref-type="ref"} In cardiac amyloidosis (CA), the aggregation and deposition of misfolded protease‐resistant amyloid fibrils in the extracellular space cause an infiltrative cardiomyopathy associated with restrictive pathophysiology and characteristic echocardiographic features including biatrial enlargement, diffuse biventricular thickening, pericardial effusion, and mild to moderate thickening of the valve leaflets.[1](#ehf212668-bib-0001){ref-type="ref"}, [2](#ehf212668-bib-0002){ref-type="ref"} There are limited case reports of amyloid deposits causing moderate to severe valvular heart disease.[3](#ehf212668-bib-0003){ref-type="ref"}, [4](#ehf212668-bib-0004){ref-type="ref"}, [5](#ehf212668-bib-0005){ref-type="ref"}, [6](#ehf212668-bib-0006){ref-type="ref"}, [7](#ehf212668-bib-0007){ref-type="ref"} Herein, we describe a rare instance of hemodynamically significant tricuspid and mitral valve stenosis because of cardiac AL amyloidosis.

Case report {#ehf212668-sec-0002}
===========

A 57‐year‐old African American male patient was first diagnosed in 2015 with multiple myeloma (60% clonal plasma cells on bone marrow biopsy) and AL amyloidosis (confirmed by fat pad biopsy; *Figure* [*1*](#ehf212668-fig-0001){ref-type="fig"}). He presented with signs and symptoms of New York Heart Association class III heart failure (elevated jugular venous pulse at 12‐cm H~2~0 and 2+ peripheral and scrotal oedema), macroglossia, and bilateral carpal tunnel syndrome. His past medical history included atrial fibrillation and stage 3 chronic kidney disease. Cyclophosphamide, bortezomib (switched to lenalidomide because of peripheral neuropathy), and dexamethasone were initiated at diagnosis as first‐line therapy. Intravenous chemotherapy was replaced by an oral regimen to enhance medication compliance in 2016, which improved light chain response. In late 2018, this regimen was replaced by the CD38 monoclonal antibody daratumumab in response to rising serum light chains, progressive CA, and recurrent admissions for decompensated heart failure (elevated jugular venous pulse at 15 cm, 3+ peripheral and scrotal oedema, and dyspnoea at rest) in the setting of ongoing patient non‐adherence.

![Light microscopy of fat pad biopsy. (A and B) Haematoxylin and eosin‐stained sections show dense amorphous eosinophilic material, characteristic of amyloid, between adipocytes and in the vessel wall, respectively (200× magnification). (C) Congo red staining shows typical dense 'orangeophilic' staining of amyloid in the vessel wall (400× magnification).](EHF2-7-1130-g001){#ehf212668-fig-0001}

Over time, serial N terminal pro BNP, troponin T, and serum creatinine levels fluctuated along with serum M proteins and light chains, coincident with progression of AL amyloidosis (*Table* [1](#ehf212668-tbl-0001){ref-type="table"}). Electrocardiograms revealed evolving conduction disease (*Figure* [*2*](#ehf212668-fig-0002){ref-type="fig"}).

###### 

Fluctuating serum biomarkers coincident with progression of light chain amyloidosis

  Parameter                                                                   At diagnosis mid‐2015                                                                                       2016                                        2017                                                       2018                                                                           2019
  -------------------------- ----------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------ --------- ---------------------------------------------------------------------------------------------------------- --------------------------------------------------
  Serum creatinine (mg/dL)                                                            1.13                                                                                                0.99                                        0.98                                                       1.47                                                                           1.38
  eGFR                                                                                \>60                                                                                                \>60                                        \>60                                                        59                                                                             53
  Troponin T (ng/mL)                                                                  0.023                                                                                              0.018                                       \<0.010                                                    0.019                                                                          0.013
  NT‐proBNP (pg/mL)                                                                   2265                                                                                                1748                                         974                                                       1093                                                                           2107
  Leukocytes (k/μL)                                                                   3.62                                                                                                2.36                                        4.08                                                       5.36                                                                           6.75
  M protein                                                                          Present                                                                                            Present                                      Present                                                   Present                                                                        Present
  Serum IgG (mg/dL)                                                                   1440                                                                                                1360                                        1430                                                       1630                                                                           1150
  Serum IgA (mg/dL)                                                                    87                                                                                                 119                                          234                                                       254                                                                            122
  Serum IgM (mg/dL)                                                                    39                                                                                                  51                                          61                                                        100                                                                             51
  Serum free kappa (mg/L)                                                             4488                                                                                               1331.2                                       628.4                                                     899.4                                                                           949
  Serum free lambda (mg/L)                                                             8.8                                                                                                11.1                                         9.4                                                       9.7                                                                            9.1
  K/L ratio                                                                            510                                                                                               119.9                                        66.9                                                       92.7                                                                          104.3
  Other relevant tests                                                            CRP 0.1 mg/dL                                                                                           ---                                          ---                                                       ---                                                      Urine K/L ratio 4478.3; procalcitonin 18.3 ng/mL
  Therapy initiated           Triple therapy: cyclophosphamide, bortezomib (stopped for peripheral neuropathy), dexamethasone; lenalidomide (added)   Switched to oral from intravenous regimen (because of patient non‐adherence)     ---     Switched to Daratumumab (given as monotherapy for disease progression because of patient non‐compliance)                          ‐

eGFR, estimated glomerular filtration rate; NT‐proBNP, N terminal pro BNP.

![Electrocardiograms demonstrating evolving conduction disease: (A) Baseline sinus rhythm with first degree atrio‐ventricular block. (B) Atrial fibrillation with left axis deviation, left fascicular block, complete right bundle branch block, and anterior lead pseudo‐infarct pattern.](EHF2-7-1130-g002){#ehf212668-fig-0002}

Transthoracic echocardiogram demonstrated features consistent with CA: normal left ventricular size, preserved ejection fraction, biatrial dilation with atrial thickening, biventricular hypertrophy (1.2--1.6 cm), trivial pericardial effusion, and abnormal myocardial global longitudinal strain (−13.9%) with relative sparring of the apex and a relative regional strain ratio of 2.1 (*Figure* [*3*](#ehf212668-fig-0003){ref-type="fig"}).

![Transthoracic echocardiogram: (A) Apical four‐chamber view demonstrating thickened mitral and tricuspid valve leaflets with evidence of restricted opening and stenosis and a trace effusion around the right atrium. (B) Parasternal short axis view of the aortic and pulmonic valves demonstrating diffuse thickening.](EHF2-7-1130-g003){#ehf212668-fig-0003}

Interestingly, transthoracic echocardiogram also had evidence of progressive valvular disease with stenosis of the tricuspid and mitral valves coincident with worsening AL amyloidosis (*Figure* [*3*](#ehf212668-fig-0003){ref-type="fig"}; *Table* [1](#ehf212668-tbl-0001){ref-type="table"}). This stenosis was further interrogated with transoesophageal echocardiogram (*Figures* [*4*](#ehf212668-fig-0004){ref-type="fig"} and [*5*](#ehf212668-fig-0005){ref-type="fig"} and *Figure* [*S1*](#ehf212668-supitem-0001){ref-type="supplementary-material"}). Transoesophageal echocardiogram demonstrated diffuse thickening of the tricuspid valve leaflets and sub‐valvular apparatus causing restricted leaflet motion and moderately severe tricuspid stenosis (mean gradient 4 mm Hg and peak gradient 8 mm Hg) and moderate tricuspid regurgitation. Similarly, there was thickening of the mitral valve leaflets leading to restricted leaflet motion and moderately severe mitral stenosis (mean gradient 9 mm Hg and peak gradient 24 mm Hg at 67 bpm; mitral valve area 1.5 cm^2^ by 3‐D‐planimetry) with mild mitral regurgitation. The aortic and pulmonic valves also demonstrated prominent and diffuse thickening, albeit without haemodynamically significant valvular stenosis or regurgitation.

![Transoesophageal echocardiogram: (A) Mid‐oesophageal four‐chamber view demonstrating diffuse thickening of the mitral and tricuspid valves with restricted opening and stenosis. (B) Three‐dimensional surgeons view of the stenotic mitral valve. (C) Three‐dimensional view from the right atrium of the stenotic tricuspid valve.](EHF2-7-1130-g004){#ehf212668-fig-0004}

![Transoesophageal echocardiogram: (A) Mid‐oesophageal aortic valve short axis demonstrating diffuse thickening of the aortic, tricuspid, and pulmonic valves and of the intra‐atrial septum and atrial wall. (B) Three‐dimensional image of the thickened aortic valve leaflets in diastole. (C) Three‐dimensional image of the thickened aortic valve leaflets in systole.](EHF2-7-1130-g005){#ehf212668-fig-0005}

Discussion {#ehf212668-sec-0003}
==========

CA carries significant morbidity and poor survival prognosis without therapy.[1](#ehf212668-bib-0001){ref-type="ref"}, [2](#ehf212668-bib-0002){ref-type="ref"} AL amyloidosis results from the accumulation of misfolded immunoglobulin light chains formed by an abnormal clone of plasma B cells and can be associated with multiple myeloma.[2](#ehf212668-bib-0002){ref-type="ref"} In AL amyloidosis, cardiac involvement drives prognosis, and prompt recognition and treatment are vital to prevent worsening heart failure.[1](#ehf212668-bib-0001){ref-type="ref"}, [2](#ehf212668-bib-0002){ref-type="ref"} Our patient experienced progressive multi‐valvular heart disease concomitant with CA progression (*Table* [1](#ehf212668-tbl-0001){ref-type="table"}; *Figures* [3](#ehf212668-fig-0003){ref-type="fig"}, [4](#ehf212668-fig-0004){ref-type="fig"}, [5](#ehf212668-fig-0005){ref-type="fig"}) with valve leaflets becoming moderately thickened, resulting in moderately severe tricuspid and mitral stenosis, with moderate tricuspid and mild mitral regurgitation because of accompanying restricted leaflet motion.

There are case reports of amyloid deposition restricted to valvular tissue because of dystrophic valvular amyloidosis.[6](#ehf212668-bib-0006){ref-type="ref"} Here, the amyloid deposits are commonly associated with localized calcified deposits and scar tissue resulting from chronic inflammation or mechanical trauma.[6](#ehf212668-bib-0006){ref-type="ref"} In a recent study of surgically excised heart valves, the prevalence of amyloid deposits was found to be highest in aortic stenosis (74%), relative to mitral stenosis or regurgitation (\~29%) and aortic regurgitation (10.5%).[4](#ehf212668-bib-0004){ref-type="ref"} Abnormal left heart valve thickening, notable in 42% of patients with confirmed AL amyloidosis, correlated with higher all‐cause mortality (hazard ratio 1.9 and *P* = 0.02), more advanced disease, worse New York Heart Association functional class, and lower 5‐year survival in these patients.[7](#ehf212668-bib-0007){ref-type="ref"} The incidence of tricuspid stenosis and regurgitation has not been well described and is very rare. While tricuspid and mitral stenosis can be seen in rheumatic heart disease, our patient did not report a past history of rheumatic fever and does not have valve calcification on imaging.[8](#ehf212668-bib-0008){ref-type="ref"} This case highlights the rare incidence of haemodynamically significant valvulopathy that can be associated with refractory CA.

The role of valvuloplasty in valvular heart disease because of CA remains unexplored. We hypothesize that valvuloplasty may not be effective in this case because valve commissures are open and the primary defect is leaflet thickening. Surgical valve replacement would be high risk because of poor outcomes with cardiac surgery in patients with restrictive cardiomyopathy.

Conclusions {#ehf212668-sec-0004}
===========

This report highlights a rare case of hemodynamically significant tricuspid and mitral stenosis caused by progressive leaflet thickening in the setting of light chain CA despite prior pharmacotherapy. Worsening clinical heart failure occurred as circulating light chains increased and valvular thickening and stenosis progressed. The role of routine valvular interventions in CA is not well defined and may be high risk because of concomitant restrictive cardiomyopathy.
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###### 

**Figure S1.** Videos of transesophaeal echocardiograms: A) Mid esophageal four chamber view demonstrating diffuse thickening of the mitral and tricuspid valves with restricted opening and stenosis. B) 3D surgeons view of the stenotic mitral valve. C) 3D view from the right atrium of the stenotic tricuspid valve. D) Mid esophageal aortic valve short axis demonstrating diffuse thickening of the aortic, tricuspid, and pulmonic valves; and of the intra‐atrial septum and atrial wall. E) 3D view of the thickened aortic valve.
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